Expression of
chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals.
CXC
chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells.
A deletion in the
chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis.
The CC
chemokine receptor 5 (CCR5) delta 32 variant results in a non-functional form of the
chemokine receptor, which is incapable of binding beta chemokines (RANTES, MIP-1alpha, MIP-1beta).
Although other
chemokine receptors have been identified that can facilitate HIV infection in vitro (7), it is now well recognized that only CCR5 and CXCR4 are the critical coreceptors for HIV infection in vivo.
In addition, some strains of HIV-1 can use a variety of other
chemokine receptors in studies in vitro, however it does not appear that they have major relevance to HIV infection in vivo and pathogenesis.
It is a short peptide that functions as a high-affinity antagonist for CXCR4, a
chemokine receptor that is directly involved in tumor progression, angiogenesis (growth of new blood vessels in the tumor), metastasis (spread of the disease to other organs or organ parts) and cell survival.
Isolating the CXCR7 receptor from potential interference by other
chemokine receptors (such as the related receptor known as CXCR4), researchers demonstrated that CXCR7 cells formed significantly larger tumors in breast and lung cancer models.
Segal notes that other kinds of cancers, such as kidney tumors, also appear to depend on the
chemokine receptor CXCR4 and so might also be thwarted by drugs blocking it.
Title: Rapid Mobilization Of CD34+ Stem Cells With TG-0054, a Novel CXC
Chemokine Receptor 4 (CXCR4) Antagonist Session Name: 711.
a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, presented data today from the company's Phase 2 clinical trial of Traficet-EN(R) (CCX282-B), an orally-active anti-inflammatory agent that targets the
chemokine receptor CCR9.
Rockville, MD) has patented human G-protein
chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques.
